Innate Pharma S.A. (IPHA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Innate Pharma S.A. (IPHA) Healthcare & Pipeline Overview

Innate Pharma S.A. is a biotechnology company focused on the discovery and development of therapeutic antibodies for oncology and inflammatory diseases, leveraging a strong clinical pipeline and strategic partnerships to advance innovative treatments.

What Is the Investment Thesis for IPHA?

The company has several assets in advanced clinical stages, including Monalizumab, which is currently in Phase III trials for various solid tumors, representing a potential market opportunity in the oncology sector valued at over $100 billion. Additionally, Lacutamab is being evaluated for multiple indications, including cutaneous T-cell lymphoma, which has a growing market as treatment options remain limited. The company’s strong gross margin of 100% reflects its focus on high-value therapeutic development, although its current profit margin of -1764.5% indicates significant investment in R&D. With ongoing collaborations with industry leaders, Innate Pharma is well-positioned to leverage these relationships for accelerated development and commercialization of its therapies. However, investors may want to evaluate the inherent risks associated with clinical trials and regulatory approvals, which could impact timelines and market entry.

Based on FMP financials and quantitative analysis

IPHA Key Highlights

Market Cap of $176M indicates a small-cap biotechnology firm with significant growth potential.

• Gross Margin of 100.0% reflects the company's focus on high-value therapeutic development.
• Profit Margin of -1764.5% highlights the current investment in R&D over profitability.
• Beta of 0.89 suggests lower volatility compared to the broader market, indicating relative stability.
• No dividend yield, typical for biotechnology firms focusing on reinvestment into R&D.

Who Are IPHA's Competitors?

IPHA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are IPHA's Key Strengths?

Robust clinical pipeline with multiple assets in advanced stages of development.

• Strong gross margin reflecting high-value therapeutic focus.
• Strategic partnerships with major industry players enhance development capabilities.
• Expertise in immuno-oncology, a rapidly growing field.

What Are IPHA's Weaknesses?

Negative profit margin indicating high R&D expenditures relative to revenue.

• Dependence on successful clinical trial outcomes for pipeline assets.
• Limited market presence compared to larger competitors.
• No current revenue streams from marketed products.

What Are the Key Risks for IPHA?

Financial-distress signal — its Altman Z-Score of -13.65 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory delays impacting the timeline for clinical trial results and product approvals.
• High competition in the biotechnology sector could affect market share and pricing.
• Dependence on successful outcomes from clinical trials for pipeline assets.
• Market volatility may influence investor sentiment and funding opportunities.

What Are the Growth Opportunities for IPHA?

• Expansion of Monalizumab: Monalizumab is currently in Phase III trials for various advanced solid tumors, including colorectal and lung cancers. The global market for immune checkpoint inhibitors is projected to reach $55 billion by 2027, driven by increasing cancer prevalence and demand for effective therapies. Successful trial outcomes could provide significant revenue streams and enhance Innate Pharma's market presence.
• Lacutamab's Clinical Development: With Lacutamab in Phase II trials targeting cutaneous T-cell lymphoma and refractory Sézary syndrome, the drug addresses unmet needs in rare cancers. The global market for T-cell lymphoma treatments is expanding, with an estimated value of over $7 billion by 2025. Positive trial results could lead to accelerated approval and market entry.
• Avdoralimab's Potential in Inflammatory Diseases: Avdoralimab is in Phase II development for various inflammatory conditions, including COVID-19. The global market for anti-inflammatory drugs is projected to grow significantly, reaching approximately $150 billion by 2028. This positions Innate Pharma to capitalize on growing demand for innovative treatments in this area.
• Strategic Collaborations: Innate Pharma's partnerships with industry leaders like AstraZeneca and Novo Nordisk A/S enhance its research capabilities and market access. These collaborations not only provide financial support but also facilitate shared expertise, accelerating the development of its pipeline assets and expanding its therapeutic reach.
• Preclinical Pipeline Advancements: The company maintains a robust preclinical pipeline, including innovative antibody programs such as IPH43 and IPH65. As these candidates progress toward clinical trials, they could provide additional revenue streams and diversify Innate Pharma's portfolio, further solidifying its position in the biotechnology sector.

What Threats Does IPHA Face?

• Intense competition from established biotechnology and pharmaceutical companies.
• Regulatory hurdles and delays in clinical trial approvals.
• Market volatility affecting investment and funding opportunities.
• Potential for adverse clinical trial results impacting stock performance.

What Are IPHA's Competitive Advantages?

• Strong pipeline of innovative therapeutic antibodies targeting high unmet needs.
• Established partnerships with leading pharmaceutical companies enhance credibility and resources.
• Expertise in immuno-oncology positions the company uniquely in a competitive landscape.
• Proprietary technologies for antibody development provide a competitive edge.
• Focus on rare and complex diseases reduces competition and increases market potential.

What Does IPHA Do?

Founded in 1999, Innate Pharma S.A. is a biotechnology firm based in Marseille, France, dedicated to the discovery, development, and commercialization of therapeutic antibodies. The company primarily focuses on oncology indications, targeting both domestic and international markets, while also addressing inflammatory diseases and viral infections. Innate Pharma's clinical-stage pipeline includes several promising assets: Lacutamab (IPH4102), an anti-KIR3DL2 antibody currently in Phase II trials for cutaneous T-cell lymphoma and refractory Sézary syndrome; Monalizumab, an immune checkpoint inhibitor in Phase III trials for advanced solid tumors; and Avdoralimab (IPH5401), a monoclonal antibody in Phase II development for various inflammatory conditions and COVID-19. Other notable candidates include IPH5201, IPH5301, and IPH6101, each targeting different immunological pathways and mechanisms. The company also boasts an active preclinical pipeline, which includes innovative antibody programs aimed at enhancing therapeutic efficacy. Innate Pharma has established strategic partnerships with major industry players such as AstraZeneca, Novo Nordisk A/S, and Sanofi, enhancing its research capabilities and market reach. This collaborative approach has positioned Innate Pharma as a significant player in the biotechnology sector, with a commitment to advancing novel therapies for unmet medical needs.

What Products and Services Does IPHA Offer?

• Discover and develop therapeutic antibodies for oncology and inflammatory diseases.
• Conduct clinical trials to evaluate the safety and efficacy of its drug candidates.
• Engage in strategic partnerships with major pharmaceutical companies for co-development.
• Maintain a diverse pipeline of both clinical-stage and preclinical assets.
• Focus on addressing unmet medical needs in oncology and immunology.
• Leverage proprietary technologies to enhance drug development processes.

How Does IPHA Make Money?

• Generate revenue through strategic collaborations and licensing agreements with pharmaceutical companies.
• Focus on developing high-value therapeutic antibodies that can command premium pricing.
• Invest in R&D to advance clinical-stage assets toward commercialization.
• Utilize milestone payments and royalties from partnered programs to supplement income.
• Seek FDA and EMA approvals to bring novel therapies to market.

What Industry Does IPHA Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, personalized medicine, and immunotherapy. The global biotechnology market is expected to reach approximately $2.4 trillion by 2028, with oncology being a significant contributor due to the increasing incidence of cancer and the demand for innovative treatments. Innate Pharma S.A. operates within this dynamic landscape, focusing on therapeutic antibodies, a segment that has seen substantial investment and innovation. The competitive landscape includes major players like Amgen, Genentech, and Bristol-Myers Squibb, but Innate Pharma differentiates itself through its specialized focus on immuno-oncology and strategic collaborations, positioning itself for growth in a rapidly evolving market.

Who Are IPHA's Key Customers?

• Pharmaceutical companies seeking innovative therapeutic solutions.
• Healthcare providers looking for advanced treatment options for patients.
• Patients with unmet medical needs in oncology and inflammatory diseases.
• Investors interested in biotechnology and healthcare sectors.
• Research institutions collaborating on clinical trials and drug development.

Company Profile

Innate Pharma S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Marseille, FR. The company is led by CEO Jonathan E. Dickinson. IPHA has traded publicly since 2019.

Key Financial Metrics

Return on assets is -78.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -35.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -34.1%, the inverse of the P/E and a quick read on earnings relative to price.

IPHA Valuation & Market Position

With a $176M market cap, Innate Pharma S.A. sits in the micro-cap segment of the market. Analyst price targets span from $4.00 to $9.00, with a consensus of $6.67. At the current price of $1.87, that implies approximately 257% upside potential. Relative to its peer group, IPHA's quantitative score of 17/100 is below the peer average of 74/100.

Quarterly Financial Performance: Innate Pharma S.A.

Revenue for Innate Pharma S.A. came in at $5.6M during Q2 FY2025, a 1660.9% improvement versus the preceding quarter. The company recorded a net loss of $24.8M, with diluted EPS of $-0.29. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.

Innate Pharma S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.65 places it in the distress zone, a signal of elevated financial risk.

Innate Pharma S.A. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 29.3% below estimates on average.

Wall Street analysts project Innate Pharma S.A. revenue of about $43.3M for fiscal 2026, with EPS near $-0.26. The estimate reflects 3 contributing analysts.

IPHA Financials

IPHA Latest News

IPHA Analyst Consensus

IPHA MoonshotScore

Latest Innate Pharma S.A. Analysis

IPHA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources